AngioLab (XKRX:251280) Change In Payables And Accrued Expense : ₩0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Change In Payables And Accrued Expense?

AngioLab's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was ₩0.0 Mil. It means AngioLab's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

AngioLab's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was ₩0.0 Mil. It means AngioLab's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

AngioLab Change In Payables And Accrued Expense Historical Data

The historical data trend for AngioLab's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Change In Payables And Accrued Expense Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial			-	-	-	-	-

AngioLab Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.0 Mil.

AngioLab Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of AngioLab's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines